TY - JOUR AU - Ho, Mei-Shang AU - Chen, Wei-Ju AU - Chen, Hour-Young AU - Lin, Szu-Fong AU - Wang, Min-Chin AU - Di, Jiali AU - Lu, Yen-Ta AU - Liu, Ching-Lung AU - Chang, Shan-Chwen AU - Chao, Chung-Liang AU - King, Chwan-Chuen AU - Chiou, Jeng-Min AU - Su, Ih-Jen AU - Yang, Jyh-Yuan T1 - Neutralizing Antibody Response and SARS Severity T2 - Emerging Infectious Disease journal PY - 2005 VL - 11 IS - 11 SP - 1730 SN - 1080-6059 AB - Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of <2 weeks (Fisher exact test, p = 0.013), and were more likely to be > 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development. KW - SARS KW - neutralizing antibody KW - antibody decay KW - mortality KW - pathogenesis KW - ADE KW - research KW - Taiwan DO - 10.3201/eid1111.040659 UR - https://wwwnc.cdc.gov/eid/article/11/11/04-0659_article ER - End of Reference